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Abstract
Background:  Modern drug discovery is concerned with identification and validation of novel
protein targets from among the 30,000 genes or more postulated to be present in the human
genome. While protein-protein interactions may be central to many disease indications, it has been
difficult to identify new chemical entities capable of regulating these interactions as either agonists
or antagonists.
Results:  In this paper, we show that peptide complements (or surrogates) derived from highly
diverse random phage display libraries can be used for the identification of the expected natural
biological partners for protein and non-protein targets. Our examples include surrogates isolated
against both an extracellular secreted protein (TNFβ ) and intracellular disease related mRNAs. In
each case, surrogates binding to these targets were obtained and found to contain partner
information embedded in their amino acid sequences. Furthermore, this information was able to
identify the correct biological partners from large human genome databases by rapid and integrated
computer based searches.
Conclusions:  Modified versions of these surrogates should provide agents capable of modifying
the activity of these targets and enable one to study their involvement in specific biological
processes as a means of target validation for downstream drug discovery.
Background
Modern drug discovery is concerned with identification
and validation of novel protein targets from among the
>30,000 genes postulated to be present in the human ge-
nome [1]. In understanding the importance of any new
gene and its connection to a given phenotype, there is the
need to know the immediate "neighborhood" of partners
for each gene product since they are most likely involved
in the action of the gene product. In this regard, there are
few if any new chemical entities (NCEs) capable of regu-
lating protein:protein interactions as either agonists or
antagonists. In the past, peptides have sometimes been
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used to obtain information about protein:protein inter-
actions as well as regulate their activity [2,3]. This has
most often been accomplished with libraries consisting
of peptides between <15 amino acids in length. Using
this approach, peptides have been identified which act as
agonists and antagonists though, in most cases, these
peptides have not shown any sequence homology to the
natural ligand [4–6]. Clearly these peptides did not use
any of the natural amino acid contacts required for bind-
ing of the growth factors to their receptors. As these pep-
tides were functional but not compositional mimics, they
lacked primary sequence information useful for identify-
ing (by motif, sequence identity or similarity) the true bi-
ological partner. These results are not surprising since
the putative contact domains between receptors and hor-
mones are expected to be conformational and short pep-
tides were probably unable to mimic a large three-
dimensional shape. In this report, we describe a novel
post-genomic approach (called Phenogenix®) that in-
volves the use of complex and random peptide libraries
of large size (up to 40 amino acids) and diversity (>1011
independent clones per library) in combination with
computational analysis for garnering information on the
natural biological partners and pathways [7]. We also
show that the specificity of these peptides can be im-
proved by mutation at the DNA level that has implica-
tions for phenotyping and the development of Site
Directed Assays. Overall, the data indicates that the sur-
rogate peptides, derived in this manner, can contain se-
quence information regarding the natural contact
domains for both protein:protein and protein:non-pro-
tein interactions.
Results and Discussion
Criteria for a Partner Hit
The first stage in the computational analysis of our sur-
rogates requires the alignment of the peptides into
groups based on motifs or consensus regions. In addi-
tion, we examine each peptide for significant differences
in the expected frequency of amino acids and the number
of times a specific peptide sequence has been repeated.
After defining our query strategy (e.g., entire surrogate
sequence, motifs, etc.), we simultaneously search several
public databases using programs such as Blastp, MAST
(Motif Alignment and Search Tool) and Patternfind (see
Materials and Methods). The output from each search is
further analyzed based on criteria described in Table 1.
Homology between the partner and surrogate oftentimes
ranges over a long stretch (15–20 amino acids) or may be
found in a perfect match within a short sequence of 5–8
amino acids (unpublished data). Other positive indica-
tors include: 1. the appearance of the partner in at least
50% of the top cohort (i.e., first 10 matches) of any one
search; 2. the appearance of the same or related hits oc-
curring in several different searches; 3. the identification
of the same partner for multiple peptides from the same
or related pans. Criterion 2 addresses the biological rele-
vance of a hit (e.g., distribution, disease indication, etc.)
and criterion 3 relates to the biological activity of the sur-
rogate and its ability to cause a phenotypic change in the
appropriate test system (phenotyping).
Panning of mRNA targets
In one series of experiments, biotinylated oligonucle-
otides comprising the UTRs (untranslated regions) of
four mRNAs were synthesized (Table 2). The oligonucle-
otides were heat denatured and allowed to anneal at
room temperature to allow the appropriate re-folding.
All of the mRNAs were subjected to 4 rounds of panning
using both 40 mer and 20 mer random libraries under
similar but not equivalent conditions. Individual phage
clones from rounds three and four were amplified, tested
for binding to the specific and a non-specific mRNA and
sequenced. Table 3 shows the overall results that were
obtained from each of the pannings. On average, about
8% of the surrogates were found to be specific for each
target when compared to a control RNA (RRE). For each
RNA target, the predicted amino acid sequences of the
peptide binders were analyzed in terms of both overall
amino acid content and the occurrence of known RNA-
binding motifs and consensus domains. Two motifs were
observed for the APP and HCV RNAs (Figure 1 and see
below). RNA binding proteins are known to have an
overall abundance of certain amino acid residues [8,9].
Table 4 shows a comparison of the specific amino acid
composition of peptide binders with regard to their aver-
age frequency of occurrence seen within the original un-
panned library. All of the peptide binders showed
enrichment of arginine residues, as would be expected
for RNA binding proteins. Also, tryptophan, serine, and
glycine residues were enriched. In addition, several pep-
tide binders showed the presence of the RGG box (Fig-
Table 1: Criteria for a Partner Hit
1. Search gives an exact match of ≥  5–7 amino acids or appearance of 
the
partner in at least 50% of the top cohort of any one search, and/or 
the
appearance of the same or related hits occurring in multiple searches.
2. Search matches an expected class of protein partners based on 
function,
cellular location or tissue/disease distribution.
3. Candidate produces a phenotype change when added into the
appropriate model systemBMC Biotechnology 2001, 1:6 http://www.biomedcentral.com/1472-6750/1/6
ure 2A) and one sequence was found that contained the
KH motif (Figure 2B), both of which are known RNA-
binding motifs [8,9]. The isolation of surrogates contain-
ing generic RNA binding motifs is not unexpected and
probably results from enhanced binding and concomi-
tant enrichment of these peptides during the panning
process. In addition, an additional consensus motif was
identified among peptides isolated by panning on RRE
RNA [10]. This motif [K/R] LRRR, aligns with a region
on the expected natural partner, the Rev peptide (Figure
3).
One peptide was chosen from each of the APP, HCV and
IGF pans (based on the highest specific binding vs. RRE
RNA) as templates for the construction of secondary li-
braries. Each of these libraries contained >1010 inde-
pendent clones and was used for panning the
appropriate target RNA. Results are shown in Figure 4
and Table 5. Since library construction was based on
peptides previously selected for binding and selectivity
to specific RNAs, the number of target-specific clones in-
creased dramatically following in vitro maturation. In
addition, motifs were observed suggesting the critical
nature of these specific residues in terms of binding to
target. Preliminary studies have shown that the second-
ary surrogates have higher relative affinities when com-
pared to the original clones (unpublished data).
In the case of the HCV RNA, we panned a sequence (AA
UUG CCA GGA CGA CCG GGU CCU UUC UUG GAU
CAA CCC GCU CAA UGC CUG GAG AUU) predicted to
bind to at least one of the proteins comprising the trans-
lation complex eukaryotic Initiation Factor 3 (eIF3; [11–
14]). Published reports identify the p120 subunit of eIF3
as the one binding to the apical loop of the domain III of
Figure 1
Peptide surrogates with RGG Box Sequences. Random pep-
tide libraries were panned on four different mRNA targets.
Isolated phage binders from rounds three and four of each
pan, were sequenced. Several peptides from each pan
showed the presence of the RGG box, a well-defined RNA-
binding motif [8,9]. RGG sequences in each surrogate is in
bold and underlined. Peptide surrogate with KH Domain.
Panning of the 20-mer random peptide library on target M1
isolated a phage clone containing the sequence VIGxxGxxF
which is similar to an RNA-binding motif, the KH motif [8,9].
The surrogate motif corresponding to the KH domain is in
bold and underlined.
Figure 2
RRE Binding Motif. Alignment of Rev peptide with surrogate
peptides containing the (K/R)LRRRP motif. surrogates were
obtained by panning a portion of the RRE mRNA using the
40 mer random peptide library. Consensus motifs are in bold
and underlined.
A  
 
M1-3-B7 RGLFTEWFRGGSWSNYRVTS 
M1-3-E8 TDGGRSVISDNVRGGSRLWLWIRHGSWSQAWGPQDAWSSK 
M1-3-H6 RVSSAQPGCTSRVRFRCPRGGLLFNGVTSTNPKTGLSNAQ 
M1-4-H1 VVYVGVLSYWPHLSGGGRLQVRCLIGRGGFGCRGG 
M2-3-C1 WPPGRTLSDLIRGGAGARGM 
M2-3-C9 SSGGLHRWSALRGGHGHGLA 
M2-3-E2 AMRLKPIAFKGPRAGAGWVEVQPCFAAFRAACTRGGSHHH 
M2-3-E3 LHAGWDVTAPRRACKGAQGPGLHGRFYCHRGGLCSGLGRC 
M2-3-E9 DEQSSLKGKLRGALVRLGMGHAMPHRGGVWPSTGRPSKQG 
M2-3-H12 WTPRHGPMRCWRHQSVFPVGAGPHWALWPIKGPRGGRTAC 
M2-NG-C7 RKTGSNIWLPLYHKVCPASTRAGNGRGGSRFLWGSMQTNC 
M3-3-B9 RLQRRGGGAVAVVWVGFGVGLLWGRLLLIILGWVLMWFLS 
M3-3-C2 QHSEHGGTEWRKRGGMAFAASFLCMRDSYRTTRLRSLLG 
M3-3-C7 GTRHVINRVRDSSGVPCKRFGGLQFSQMGKCTIPRGGA 
M4-NG-A4 VLRGGSVGKGSLMWCQEVDWRTGGPRSNLWGLWNGRQPPK 
 
 
B  
 
KH Motif   VIGxxGxxF 
M1-3-C6 GVIGGRGLLFPLSGFLHQHR 
 
 
Rev Peptide                TRQARRNRRRRWRERQR 
 
SURROGATES   SEQUENCE 
 
CONSENSUS:                (K/R)LRRRP 
RRE-NG-C9       ATNFARSQGTQVRGMDVGRLRRRPLEAQGTSGCWWSRVSC 
RRE-NG-C2     PAFRQVHWRILAGRDWPIADRFRRQPGGSSSGRSHF 
RRE-NG-B5 QSHSLFWHGFTDMRCRWQTGSISKLRRRPAVL-GVSRSPCT 
Figure 3
surrogate Maturation. One clone for each of the three tar-
gets – APP, HCV, and IGF was identified for generation of
secondary libraries. Residues that were selected for after
four rounds of panning are indicated in bold and underlined.
Table 2: Description of targets used for the mRNA pans
MRNA Length (nucleotides) Binding 
Protein
APP (Amyloid Precursor 48 Unknown
Protein)
HCV (Hepatitis C Virus) 51 EIF3 [10–13]
IGF-1 (Insulin-like Growth 61 Unknown
Factor-1
RRE (Rev Response 47 Rev [10]
Element
 
APP VARVRLNRTSPHCGRAPPKAWSFLLVRRQPSPCALVKNPA 
HCV RVLDKRRSAQGRQNAYYIVPWRACRPLIGALSGRPRLGCG 
IGF QYWKARPYQSAPVVRNWFRCQVGVPGRQTGSSRADPGCP 
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HCV 5'UTR, and p170 (also called p160) as binding the
stem portion of the domain III. The oligonucleotide used
for these studies contains the apical portion and part of
the stem portion of domain III and, therefore, might
bind one or both of these subunits. Interestingly, the
binding of p170 (p160) to the stem of domain III is posi-
tion-independent (i.e., not constrained by other struc-
tural elements on the mRNA [12,13]).
Sequence analysis of surrogate peptide binders to HCV
using MEME (Motif Elicitation Program) and other pep-
tide sequence alignment programs identified a consen-
sus sequence TxRLL found in four peptides binding to
the HCV mRNA (Figure 5). This motif was unique to
HCV and not found in peptides derived from any of the
other mRNA pans. Interestingly, the TxRLL-containing
surrogates were found by two investigators in the labora-
tory, using the 20 mer or 40 mer random libraries under
different experimental conditions. Database searches us-
ing Patternfind at the ISREC server were performed us-
ing parameters appropriate for short protein queries and
were successful in identifying a human gene product,
subunit p170 of eIF3 (Figure 3). Searches using the con-
Table 3: Results of panning experiments on selected mRNA targets using the primary phage displayed peptide libraries
RNA # Picked # Binders # Specific Signal Signal
Target (%) Binder (%) Ratios/SA Ratios/RNA
APP 240 186 (78) 21 (11) 19.6 7.4
HCV 240 207 (86) 31 (15) 16.7 7.9
IGF-1 240 184 (77) 9 (5) 18.7 3.1
RRE 48 25 (42) 4 (16) 25.3 2.3
Individual clones were picked after three to four rounds of panning of random peptide displayed phage libraries for four different RNA targets. 
Phage rescued from these clones were tested for binding to the specific RNA target and an irrelevant RNA target. Clones that had a binding ratio 
of ≥  2.0 over streptavidin (SA) background were categorized as binders. Binders were then sub-categorized as specific binders if they had a binding 
ratio of target:irrelevant ≥  2.0.
Table 4: Comparison of Amino Acid Frequency in surrogates with expected frequencies.
Arg Gly Trp Ser
Expected 9.4 6.3 3.1 9.4
Frequency
Library 9.4 11.6 3.1 7.7
M1 13.9 12.6 5.2 10
M2 13 13 4.3 8.3
M3 12.4 12.3 5.1 9.8
The expected frequency of each amino acid within the library was calculated based on the probability of occurrence for each codon in the library. 
These data were compared to the actual frequency of occurrence in the library before and after panning on the various mRNA targets denoted as 
M1, M2, and M3. All numbers are expressed as a percentage of the expected frequency.
Figure 4
HCV-eIF3 Binding Motif. Alignment of eIF3 with surrogate
peptides containing the TxRLL motif. surrogate peptides
were obtained by panning a portion of the 5'UTR of HCV
mRNA using both the 20 mer and 40 mer random libraries.
Peptides HCV-3-F5 and HCV-3-H8 were obtained from the
40-mer library from the same pan. Peptide HCV-NG-D9 was
obtained from the 40 mer library using modified experimen-
tal conditions. Peptide HCV-3-C3 was obtained from the 20
mer library. Consensus sequences are in bold and under-
lined. Sequences outside the motif that are conserved
between the surrogates and eIF3 are in Italics and underlined.
 
 
eIF3: EDLDNIQTPE-SVLLSAVSGEDTQDRTDRLLLTPWVKFLWESY 
 
CONSENSUS:                            TxRLL 
 
HCV-NG-D9                   TSGESSGDRTRRVLTSSSARTLPN 
HCV-3-F5   LLVTGQFP--SQLLLGGAVCGP--STPRLRTGLCRLSGT 
HCV-3-H8 RRTCGDPAAMLERLSCRAGDYRGASHTGRLLNLRGMHQYP 
HCV-3-C3                          FTTPRHLSGRTVQMMRDSTS BMC Biotechnology 2001, 1:6 http://www.biomedcentral.com/1472-6750/1/6
sensus region as the query likewise identified sequence
homology with the large subunit p170 of eIF3. These re-
sults fit our partner criteria 1–3 (Table 1). Interestingly,
other amino acids in these surrogates were found to be
identical to residues flanking the TxRLL motif in p170
on both the amino and carboxy sides (Figure 5). Thus,
the library contained peptide surrogates binding to the
HCV target mRNA as well as containing sequence infor-
mation identifying the natural interacting partner and
predicting the putative contact amino acids on the p170
subunit of eIF3. The fact that multiple surrogates had the
TxRLL motif suggests that this region of p170 is neces-
sary and critical for binding of HCV mRNA to eIF3.
Panning of TNF-β
In a separate study, we panned the immune cytokine
TNF-β  (lymphotoxin α , Lt α ; [15–17]) using a highly
stringent protocol involving both positive (vs. TNF-β )
and negative (vs. TNF-α , TNFR1 and TNFR2) selection.
One of these peptides, designated KcB7, had the amino
acid sequence RKEMGGGGGPGWSENLFQ. A
Blastp search, using several different queries revealed
TNFR1, which is the natural biological partner of TNFβ
(Figure 5). Interestingly, the other cognate partner (i.e.,
receptor TNFR2) was not identified. Closer examination
of the complementary sequences revealed that the short
N-terminal sequence RKEMG and the C-terminal se-
quence WSENLFQ were identical to regions on TNFR1
(amino acids 77–81 and 107–113 respectively). Although
not complete, these segments corresponded to amino ac-
ids within two critical ligand:receptor contact domains
[18]. In the case of the N-terminal grouping, the surro-
gate contained 5 of the 15 amino acids of the 77–81 con-
tact domain whereas in the C-terminal grouping, the
surrogate contained 6 of the 9 amino acids identified
within the 107–113 contact domain. It is also worth not-
ing that, on the receptor, these two domains are not con-
tiguous but are separated by 25 amino acids whereas
only a 6 amino acid hydrophobic stretch separates the
two noncontiguous contact-mimicking domains in the
surrogate. Therefore, the seven amino acid linker may
provide the appropriate molecular distances needed for
TNFβ  binding to the receptor.
Robustness of the System
The successful isolation of a useful surrogate may seem
an improbable task especially in cases where nothing is
known about the hotspot surface(s) on a target. In reali-
ty, biopanning using the RAPIDLIB® library has al-
lowed, (in >90% of cases) the identification of partner-
specific peptides among the >1010-11independent clones
that are expressed within this library [[7,19,20] and un-
published data]. More often than not, between 10 and
100 different surrogates have been found for any one tar-
get panned and >75% of the targets gave rise to surro-
gates that bound to regulatory hotspots on the target [[7]
and unpublished data]. Several important facts are criti-
cal to the success of the process. In the first place, there
must be a high degree of diversity within the library so
that one surrogate can be found for each protein target.
Additionally, It appears that panning seems to favor the
enrichment of regulatory surrogates versus irrelevant
peptides. In our experience, the large number of random
peptides includes a broad sampling of linear and confor-
mational protein surfaces sufficient to present at least
one low affinity "complement' for any target's surface
[19,20]. The immune system's antibody repertoire arises
through a process [21–24] similar to in some aspects to
what occurs during the panning process. Initially, immu-
noglobulins are synthesized containing multiple small
contact domains (i.e., CDR or Complementarity Defining
Regions) to provide a "rough" complement of an anti-
gen's surface. Subsequently, antibody/antigen binding is
improved via mutational events within the antibody
genes to produce a complement with higher affinity and
selectivity. Biopanning works in an analogous manner by
initially enriching for peptides with low affinity for a spe-
cific target. However, surrogates may only need to con-
tain some amino acids identical to those on the partner
to bind with sufficient "avidity" rather than affinity.
Table 5: Results of panning experiments on RNA targets using secondary libraries
Target Primary Secondary Target Specific Target Specific
Binder Binder (%) Binders: Primary Binders: Secondary
(%) (%) (%)
APP 78 95 9 40
HCV 86 98 13 17
IGF-1 77 99 4 18
Clones were categorized as specific binders if they had a binding ratio of target:irrelevant ≥  2.0, as described in Table 2 above. Comparison of per-
centage specific binders from pannings of primary libraries (expressing random peptides) vs. secondary libraries (based on target-specific primary 
surrogates) is shown in this Table.BMC Biotechnology 2001, 1:6 http://www.biomedcentral.com/1472-6750/1/6
Other methods that have been used extensively for high
throughput partner identification include the yeast two-
hybrid system [25]. While the two hybrid approach is
popular, it has a number of inherent problems including
a high potential for false positives, the inability to use
non-protein targets such as mRNA or membrane bound/
extracellular proteins and the inability to address pos-
translational modifications on a target. The generation
of surrogates, on the other hands, is target independent
and their utility for partner identification resides in the
computational analysis of the peptide's sequence. Since
our libraries contain totally random peptides ranging
from 20 and up to 40 amino acids in length, there are no
known restrictions on the amino acids that can be select-
ed to create the surrogate's 'complementary' surface [7].
Thus, the examples described in this report relate to the
utility of the surrogate approach for finding the cognate
receptor for both protein and non-protein targets. In the
case of the surrogates for both HCV-mRNA and TNFβ , it
is clear that the large diversity and size of the original li-
brary was, in fact, critical to their successful isolation
since libraries of <20 amino acids would not have con-
tained either the KcB7 peptide or the HCV-specific sur-
rogates.
In addition to the data presented in this paper, we have
screened other targets using this approach. While the ex-
pected natural partners were found for many of the pro-
teins, there were instances where surrogates were
generated but lacked partner information (e.g., IGF-1R,
growth hormone receptor, insulin receptor [[7] and
manuscripts in preparation]). There are several possible
explanations for these results. While our libraries are
large and diverse, it is probable that identification of a
surrogate peptide with partner information is a rare
event. With that in mind, it may require the isolation and
sequencing of large numbers of clones (perhaps >500/
target) in order to find the appropriate surrogate for
partner identification. On the other hand, some targets
may have complex or unusual protein:protein contact
sites that preclude generation of a surrogate with partner
information. Ongoing experiments will address both of
these possibilities. Surrogates have also been found to
have the minimal structural content necessary to induce
a pharmacological effect on any target in addition to
their use in partner identification. Most of our surrogates
have been shown to have either agonist or antagonist ac-
tivity in the appropriate biochemical and/or biological
models ([7]manuscripts in preparation). The surrogates
were also able to subdivide large contact surfaces into
smaller contact domains through which target activity
can be modified [7]. These attributes point to surrogate
use in phenotyping and validating novel genes whose
functions are unknown and for which no known partners
exist. Finally, it is worthwhile to note that surrogates
have been used to develop competitive Site Directed As-
says (SDAs) for essential sub-domains thereby allowing
their use in high throughput screening of large combina-
torial libraries of small molecules (unpublished data). In
our experience, almost all of the peptide surrogates iso-
lated from these complex libraries by our various pan-
ning procedures bind to regulatory hot spots on varied
targets. This non-random association between a surro-
gate and a target's  pharmacologically active site assures
a high degree of probability that, once found, surrogates
will have utility for the rapid development of SDAs capa-
ble of identifying small molecules of pharmacological
importance.
Conclusions
The results of these experiments support the use of in
vitro panning procedures with our highly complex and
random 20–40 mer peptide libraries as a method to ob-
tain information on large numbers of protein partners
and enable the elucidation of biologically relevant pro-
tein networks. This post-genomic approach can be auto-
mated to increase the number of known and unknown
genes and gene products that can be used as targets for
partner identification as the first step in the drug discov-
ery process. Additionally, the surrogates isolated in such
studies would be prime candidates for phenotyping and
target validation through their ability to regulate target
activity and for identifying small molecule drug leads
through their use in Site Directed Assays. Overall, the
surrogates can be seen as providing a discovery continu-
um by bridging the gap between functional genomics and
proteomics and modern drug discovery.
Figure 5
Alignment of the TNFβ  surrogate peptide KcB7 with its cog-
nate receptor TNFR1 (p55). Peptide KcB7 was isolated by
panning TNFβ . The peptide has the sequence RKEMG-
GGGGPGWSENLFQ and a BLASTp search revealed
identity to amino acids 77–81 (RKEMG) and amino acids
107–113 (WSENLFQ) on TNFR1 (p55). RKEMG is
involved in binding of TNFR1 to the A subunit of TNFβ  while
WSENL binds to several amino acids in the C subunit of
TNFβ
RKEMGGGGGGPGWSENLFQ 
 
ESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTVCGCRKNQYRHYWSENLFQCF
aa 77-81  aa 107-113 
TNFR1 
Surrogate KcB7 BMC Biotechnology 2001, 1:6 http://www.biomedcentral.com/1472-6750/1/6
Materials and Methods
Targets
Oligonucleotides for the mRNA pans were synthesized
by Dharmacon Research (Lafayette, CO) and used for the
experiments after heat treatment and re-annealing (65°
for 10' and slow cooling at room temperature). The APP
and IGF oligo sequences are proprietary to Message
Pharmaceuticals. The following sequence was used to
obtain the HCV surrogates: 5'-biotin'AA UUG CCA GGA
CGA CCG GGU CCU UUC UUG GAU CAA CCC GCU CAA
UGC CUG GAG AUU-3'. The sequence for RRE (Rev-re-
sponse element) has been previously published [10].
Streptavidin coated plates were obtained from Pierce
(Rockford, IL). TNFR1, TNFR2, TNF-α  and TNF-β  were
obtained from R&D Systems (Minneapolis, MN) and re-
constituted according to the manufacturer's instruc-
tions. The E. coli, strain TG1 (genotype = K12∆ (lac-pro),
supE, thi, hsd∆ 5/F' [traD36, proAB, lacI q, lacZ∆ M15])
was obtained from Pharmacia (Piscataway NJ).
Design of the Primary Peptide Libraries
DNA fragments coding for peptides containing 40 ran-
dom amino acids were generated by a PCR approach us-
ing synthetic oligonucleotides as previously described
[7,26]. Peptides are expressed on the capsid protein pIII
of the phage at low copy number (1–2 peptides/phage).
Construction of secondary cell libraries
Amino acid mutations were introduced at the oligonucle-
otide level under controlled conditions [7]. This oligonu-
cleotide was used as the template in a PCR reaction with
two shorter 5' biotinylated oligonucleotide primers con-
tributing the restriction sites. The library was then pro-
duced essentially as previously described (above). Cell
transformants were pooled and an aliquot was plated to
determine the total number of transformants. The diver-
sity of the secondary cell libraries >1010 independent
clones per library.
Biopanning and ELISA protocols
For the TNF experiments, 6 wells of a 96-well microtiter
plate (Maxisorb Immuno plates, Nunc) are coated with
target at concentrations ranging from 5–50 ng/well and
are incubated overnight at 4°C. At the same time, an al-
iquot of E. coli TG1 cells is inoculated into 2x YT media
and grown overnight at 37°C. The next day, unbound an-
tigen is removed and the coated wells are blocked with
300 µl of 2% non-fat milk in PBS (NFM-PBS) for one
hour at room temperature. The phage libraries (in NFM-
PBS) are thawed and 100 µl of each library is added to the
antigen-coated wells and the plates are incubated for 3
hours at room temperature. Each well is washed 13 times
with PBS and the phage eluted with 100 µl of 50 mM gly-
cine-HCl containing 0.1% BSA (pH2.2) following a five
minute incubation. The eluted phage are pooled, neu-
tralized with 100 µl of 1 M Tris-HCl (pH 8.0). The eluted
phage were then panned vs. other members of the TNF
family as a way to obtain peptides specific to the original
target (Subtractive panning). For example, phage, ini-
tially panned vs. TNF-α  would be subsequently panned
vs. TNF-β , TNFR1 and TNFR2 to remove peptides cross-
reacting with the other members. After the final panning,
the phage are added to 10 ml of log phase E coli TG1
(OD600 = 1.0), and amplified in 2x YT-glucose medium
for one hour at 37°C. Helper phage (M13K07) and ampi-
cillin are then added and the cells are incubated for an
additional hour at 37°C. The cells are pelleted at 3500
RPM for 10 minutes, resuspended in 2x YT-AK medium
(YT medium containing ampicillin and kanamycin) and
incubated overnight at 37°C. The next day, the infected
bacterial cells are centrifuged at 3500 RPM at 4°C for 10
minutes and the pellet discarded. The supernatant con-
tains the phage and is precipitated with 1/4 volume of
20% PEG-8000 in 1.6 M NaCl by incubating on ice for 1
hour. The precipitant is centrifuged at 10,000 RPM at
4°C for 10 minutes and the precipitated phage pellet re-
supended in about 1 ml of NFM-PBS. The phage is then
used for the next round of panning. Normally, 3–4
rounds of panning are done for secondary libraries. Usu-
ally, 96 random clones are picked from rounds 3 and 4
and grown in 96 well cluster plates as a master stock.
For the mRNA pans, all solutions and surfaces are pre-
treated with DEPC or RNaseZap (Ambion, Austin TX),
respectively, to eliminate RNase contamination that may
compromise the integrity of the RNA. The biotinylated –
RNA target diluted to 1 mg/ml in binding buffer (PBS
containing 1 mM MgCl2), denatured at 65°C for 5 min
and reannealed by slow cooling to room temperature.
Re-annealed mRNAs are stored in small aliquots (10–25
µl/tube) at -20°C. Microtiter wells are treated with RNa-
seZap (Ambion) before use. One hundred microliters of
RNA solution diluted to 2.5 ng/ µl was added to an ap-
propriate number of wells in a 96-well microtiter plate
precoated with Streptavidin (Pierce) and incubated for 1
hr at room temperature. Unbound streptavidin is then
blocked with 50 µl of 2 mM biotin at room temperature
for 1 hr. Panning, with slight modifications, proceeded as
described for TNF-β .
For phage rescue prior to ELISA analysis, 40 µl of master
stock is transferred from each master to another set of
cluster tubes containing 400 µl of 2x YT-AG (ampicillin
and glucose) and helper phage (final concentration of 5 ×
1010/ml). The tubes are incubated at 37°C with constant
shaking for two hours. The cultures are centrifuged at
2500 ×  g at 4°C for 20 minutes, the supernatant is dis-
carded, and the bacterial pellet is resuspended in 400 µl
of 2x YT-AK (ampicillin and kanamycin) medium and is
incubated overnight at 37°C. At that time, the cells are re-BMC Biotechnology 2001, 1:6 http://www.biomedcentral.com/1472-6750/1/6
moved by centrifugation at 2500 ×  g and the superna-
tants used for ELISAs (see below).
Enzyme Linked Immunosorbent Assays (ELISA)
For the TNF-β  surrogate ELISAs, each well of a Max-
iSorp Immuno plate (Nunc) is coated with 50 µl of target
(1 µg/ml) overnight at 4°C. In all cases, the wells are
blocked with NFM-PBS for 1 hour at room temperature.
Phage is added at 100 µl/well and the plates incubated
for 2–3 hours at room temperature. After washing 3x
with PBS-Tween (DPTC-treated PBS for the mRNA),
plates are probed with an anti-M13 antibody conjugated
to horseradish peroxidase (1:3000 in PBS-NFM) for 1
hour at room temperature followed by addition of 100 µl
of ABTS for 15–30 minutes at room temperature. The
OD is measured using a SpectraMax Microplate Spectro-
photometer (Molecular Devices) at 405 nm after a 30
minute incubation at room temperature.
The mRNA ELISAs are performed in a similar manner
except streptavidin-coated microtiter plates are blocked
with PBS containing 2% non fat milk for 1 hr at room
temperature, treated with RNaseZap, then coated with
biotinylated RNA target (100 ng/well) by incubation for
1 hr at room temperature. Superasin was added to the
wells prior to addition of 100 µl/well of phage from iso-
lated clones and incubated at room temperature for 2 hr.
Steps in computational analysis to identify natural partner
Once a surrogate peptide binder has been identified and
shown to bind specifically to its target, it is subjected to
partner analysis using several different database search
programs. In the initial step, the entire peptide sequence
and consensus motifs (if found) are entered into an Ad-
vanced BLAST search  [http://www.ncbi.nlm.nih.gov/
blast/blast.cgi?Jform=1] : using the following parame-
ters:
i. Programs: blastp, tblastn
ii. Databases: protein and nucleotide databases includ-
ing dbest (ESTs), dsts (STSs) and htgs (unfinished high
throughput genomic sequences)
iii. Expect value: 1000 to 20000
iv. Matrix: PAM30 or PAM70
v. Query: Consensus motif alone and varying combina-
tions of sequence at the N- and C-terminal ends
In subsequent steps, motifs identified by sequence align-
ment programs like MEME (Multiple EM for Motif Elic-
itation),  [http://meme.sdsc.edu/meme/website/
intro.html]  can also be used to search the available data-
bases using MAST (Motif Alignment and Search Tool,
[http://meme.sdsc.edu/mem/website/mast-in-
tro.html] ). Motifs and consensus domains can also be
used as query patterns to search the protein databases
using Patternfind  [http://www.isrec.isb-sib.ch/soft-
ware/PATFND_form.html] .
For Patternfind, the following parameters are used:
i. Databases: Nonredundant, Swissprot, TREST and
TRGEN
ii. Limit: Between 10 and 5000
iii. Query: Consensus motif alone and varying combina-
tions of sequence at N- and C-terminal ends
Data obtained from the various searches are analyzed
under the following conditions:
i. Results of different searches should be analyzed inde-
pendently and then together to look for similar classes of
proteins (e.g., Nucleic acid binding proteins, kinases)
that may emerge.
ii. Pick some of the best matches that show up in more
than one kind of search (e.g. Same protein/ORF picked
up by BLAST searches using different parameters, or by
both BLAST and Patternfind) and compare sequence of
protein in this region with other peptide surrogates con-
taining this motif.
iii. Look at potential significance of protein interaction in
the context of the cellular function of target
The criteria for a partner hit are listed in Table 1. Unless
there is an exact match (Criterion No. 1), the potential hit
has to match at least two of the criteria described in the
table to be considered a partner hit.
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